Boehringer Ingelheim Chairman Andreas Barner On Emerging Markets Strategy: From Clinical Trials To Commercial Launches
This article was originally published in PharmAsia News
Although late in the game, Boehringer Ingelheim has set its sights on growth markets like India and in everything that it has planned, an innovative approach holds the key.
You may also be interested in...
Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.
The two drug makers will jointly develop four diabetes drugs: two oral agents from Boehringer Ingelheim and two basal insulin analogues from Lilly.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.